Renin as a target of direct pharmacological block in arterial hypertension


Cite item

Full Text

Abstract

Renin is a basic component of renin-angiotensin-aldosteron system which contributes much to the activity of this system. Renin and its precursor prorenin can interact with prorenin receptors thus inducing hypertrophy and fibrogenesis in target tissues. Many variants of arterial hypertension are associated with plasmic renin activation suggesting high efficacy of direct renin inhibitors. Large controlled clinical trials demonstrated that one of such inhibitors, aliskiren, reduces high blood pressure and damage to target organs.

References

  1. Lindop G. B. M. Morphological aspects of renin synthesis, processing, storage and secretion. Kidney Int. 1987; 31(suppl. 20): 18-24.
  2. Takahashi S., Murakami K., Miyake Y. Activation of kidney prorenin by kidney kathepsin В isozymes. J. Biochem. 1982; 91: 419-422.
  3. Skott O. Renin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002; 282: R937-R939.
  4. Серов В. В., Пальцев М. А. Почки и артериальная гипертензия. М.: Медицина; 1993.
  5. Textor S. C., Wilcox C. S. Renal artery stenosis: a common, treatable cause of renal failure? Ann. Rev. Med. 2001; 52: 421-442.
  6. Федоров В. И., Перов Ю. Л. Резервная продукция ренина мезангиальными клетками клубочка при экспериментальном уменьшении почечного кровообращения. Бюл. экспер. биол. 1977; 83 (6): 656-659.
  7. Пальцев М. А., Кротовский Г. С., Егорова И. А., Щербюк А. Н. Состояние нейроэндокринных аппаратов почек при вазоренальной артериальной гипертензии как критерий прогнозирования результатов оперативного вмешательства. Арх. пат. 1982; 8: 62-71.
  8. Persson Р. В. Renin: origin, secretion and synthesis. J. Physiol. 2003; 552 (3): 667-671.
  9. Wagner C. Function of connexins in the renal circulation. Kidney Int. 2008; 3 (5): 547-555.
  10. Gomez R. A., Sequeira Lopez M. L Who and where is the renal baroreceptor: the connexin hypothesis. Kidney Int. 2009; 75 (5): 460-462.
  11. Chen M., Schnermann J., Smart A. M. et al. Cyclic AMP selectively increases renin mRNA stabilityin cultured juxtaglomerular granular cells. J. Biol. Chem. 1993; 268: 24138-24144.
  12. Krop M., Danser A. H. J. Circulating versus tissue angiotensin system: on the origin of (pro)renin. Curr. Hypertens. Rep. 2008; 10: 112-118.
  13. Nguyen G., Delarue F., Burcklé C. et al. Pivotal role of the rennin/pro-renin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002; 109: 1417-1427.
  14. Danser A. H. J., Deinum J. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005; 46: 1069-1076.
  15. Oliver J. A. Receptor mediated actions of renin and pro-renin. Kidney Int. 2006; 69: 13-15.
  16. Huang Y., Wongamorntham S., Kasting J. et al. Renin increases mesangial cell transforming growth factor-beta 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006; 69: 105-113.
  17. Nguen G., Danser A. H. J. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 2008; 93 (pt 5): 557-563.
  18. Ichihara A., Suzuki F., Nakagawa T. et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type la receptor-deficient mice. J. Am. Soc. Nephrol. 2006; 17: 1950-1961.
  19. Kaneshiro Y., Ichihara A., Sakoda M. et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)rennin receptor-transgenic rats. J. Am. Soc. Nephrol. 2007; 18: 1789-1795.
  20. Krebs C., Hamming I., Sadaghiani S. et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int. 2007; 72: 725-730.
  21. He M., Zhang L, Shao Y. et al. Inhibition of reninprorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur. J. Pharmacol. 2009; 606 (1-3): 155-161.
  22. Fisher N. D. L., Hollenberg N. K. Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. 2005; 16: 592-599.
  23. Staessen J. A., Li Y., Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449-1456.
  24. Johnson C. A., Wakerlin G. E. Antiserum for renin. Proc. Soc. Exp. Biol. (N 4). 1940; 44: 277-281.
  25. Haber E., Burton J. Inhibitors of the renin and their utility in physiologic studies. Fed. Proc. 1979; 38: 2768-2773.
  26. Boger J., Lohr N. S., Ulm E. H. et al. Novel renin inhibitors containing the amino acid statine. Nature, 1983; 303 (5912): 81-84.
  27. Himmelmann A., Bergbrant A., Svensson A. et al. Remikiren (Ro 42-5892)-an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am. J. Hypertens. 1996; 9: 517-522.
  28. Oh B.-H., Mitchell J., Herron J. R. et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol. 2007; 49: 1157-1163.
  29. Fisher N. D., Jan Danser A. H., Nussberger J. et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117 (25): 3199-3205.
  30. Dahlof В., Anderson D. R., Arora V. et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension (abstr). J. Clin. Hypertens. 2007; 9 (suppl. A): A157.
  31. Mooser V., Nussberger J., Juillerat L. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 1990; 15 (2): 276-282.
  32. Bleich M., Greger R. Mechanism of action of diuretics. Kidney Int. 1997; 51 (suppl. 59): S11-S15.
  33. Oparil S., Yarows S. A., Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomiased. Double-blind trial. Lancet 2007; 370: 221-229.
  34. Schmieder R. E., Philipp Т., Guerediaga J. et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren. a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-425.
  35. Чазова И. Е., Ратова Л. Г. Комбинированная терапия артериальной гипертонии. Сердце 2005; 4 (3): 120-126.
  36. Luetscher J. A., Kraemer F. B., Wilson D. M. et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular comlications. N. Engl. J. Med. 1985; 312: 1412-1417.
  37. Chiarelli F., Pomilio M., De Luca F. A. et al. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr. Nephrol. 2001; 16: 116-120.
  38. Kelly D. J., Zhang Y., Мое G. et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50 (11): 2398-2404.
  39. Parving H. H., Persson F., Lewis J. B. et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008; 358 (23): 2433-2446.
  40. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 2009 [Epub Ahead of Print]; gfn721v1-gfn721.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies